Research

Hormonal

Tirzepatide (5, 10, and 15 mg) is a cost-effective treatment for weight management compared to liraglutide in the UK, demonstrating dominance (cost savings and QALY gains) in the general obesity trial population and favorable ICERs in the specific NICE-reimbursed population.

For patients in the UK with obesity or overweight plus complications, tirzepatide (5, 10, or 15 mg weekly) combined with diet and exercise is a cost-effective treatment option compared to liraglutide. It offers potential cost savings and quality-of-life gains, and unlike liraglutide which is restricted to specialist services, tirzepatide can be prescribed in primary care.

GoodSupportsHIGH confidence
In the trial population, all doses of tirzepatide were dominant to liraglutide, with estimated cost savings and QALY gains. In liraglutide’s UK recommended population the estimated ICERs for tirzepatide vs liraglutide were £5401–7864/QALY gained across doses
Matthew Capehorn et al. · Advances in Therapy · 2025

Why this rating

Based on a simulation model informed by network meta-analysis and trial data, not a direct head-to-head RCT.

Source

Cost-Effectiveness of Tirzepatide Versus Liraglutide, Both Adjunct to Diet and Exercise, for Patients with Obesity or Overweight: A UK Perspective

Matthew Capehorn et al. · Advances in Therapy · 2025

DOI 10.1007/s12325-025-03288-3

unknownCited 1×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →